Indaptus Therapeutics, Inc. · NASDAQ:INDP
Indaptus Therapeutics — Investor Presentation (October 2022)
26 slides from Indaptus Therapeutics's investor presentation, October 2022
Slide 1: Corporate Presentation
October 2022 CORPORATE PRESENTATION NASDAQ: INDP
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward‐looking statements with the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things, our product development efforts, busi
Slide 3: Investor Highlights and Key Metrics
INVESTOR HIGHLIGHTS AND KEY METRICS • Clinical-stage asset preparing to enroll Phase 1 clinical trial in solid tumors STOCK SYMBOL: INDP (NASDAQ CM) • Innovative and flexible clinical platform Stock Price (10/5/22) $2.19 based upon application of proven scientific principals 52 Week Range $1.89 - $8
Slide 4: Summary of Indaptus Technology
SUMMARY OF INDAPTUS TECHNOLOGY Decoy therapeutics exhibit many unique properties • Single agent anti-tumor activity • Tumor eradicating synergy with several different existing therapies • Reduced toxicity and broad therapeutic index • Safe induction of both innate and adaptive immune pathways • Inna
Slide 5: Current cancer immunotherapies only address a limited part of the immune system
CURRENT CANCER IMMUNOTHERAPIES ONLY ADDRESS A LIMITED PART OF THE IMMUNE SYSTEM AND THEREFORE HAVE LOW CURE RATES IN ADVANCED CANCERS Targeted Antibodies IL-2 and IFN-α T-vec/GM-CSF Checkpoint CAR-T Gamma- TAA Delta Natural Killer T-Cell T-Cell Natural Killer Cell Dendritic Cell INNATE ADAPTIVE Neut
Slide 6: Solution - Let Nature Be Our Guide
SOLUTION - LET NATURE BE OUR GUIDE Existing Cancer Immunotherapies • Don’t prime or activate both the innate and adaptive immune pathways • Require continuous, systemic exposure - producing significant risk of toxicity NASDAQ: INDP 6
Slide 7: Solution - Let Nature Be Our Guide
SOLUTION - LET NATURE BE OUR GUIDE Existing Cancer Immunotherapies • Don’t prime or activate both the innate and adaptive immune pathways • Require continuous, systemic exposure - producing significant risk of toxicity Nature’s Example: A More Optimal Innate and Adaptive Immune Response • Foreign th
Slide 8: Solution - Let Nature Be Our Guide
SOLUTION - LET NATURE BE OUR GUIDE Existing Cancer Immunotherapies • Don’t prime or activate both the innate and adaptive immune pathways • Require continuous, systemic exposure - producing significant risk of toxicity Nature’s Example: A More Optimal Innate and Adaptive Immune Response • Foreign th
Slide 9: The World's First Multi-Targeted Pulse Priming (MTPP) Immunotherapy
THE WORLD’S FIRST MULTI-TARGETED PULSE PRIMING (MTPP) IMMUNOTHERAPY DECOY Targeted Antibodies IL-2 and IFN-α T-vec/GM-CSF Checkpoint CAR-T Gamma- TAA Delta Natural Killer T-Cell T-Cell INNATE Natural Killer Cell Dendritic Cell ADAPTIVE Neutrophil CD8+ T-Cell TAA Macrophage CD4+ T-Cell NASDAQ: INDP T
Slide 10: Challenge - IV Administered Gram-Negative Bacteria Are Toxic
CHALLENGE – IV ADMINISTERED OF GRAM- NEGATIVE BACTERIA ARE TOXIC Analyzing this approach with today’s information: • TLR4 agonist LPS-endotoxin constitutes ~75% of the Gram-negative outer cell membrane • LPS has been shown to be one of the most potent and broadly acting innate and adaptive immune sy
Slide 11: Producing a Multi-Targeted Package of Immune System Activating Signals
PRODUCING A MULTI-TARGETED PACKAGE OF IMMUNE SYSTEM ACTIVATING SIGNALS – A RE-INVENTING OF THE APPROACH DECOY PRODUCT: RESULT AND PREDICTIONS A MULTI-TARGETED IMMUNE ACTIVATOR • Start with a single, pure strain of • Decoy therapeutics contains multiple TLR non-pathogenic, Gram-negative bacteria agon
Slide 12: Indaptus Clinical Development Plan
INDAPTUS CLINICAL DEVELOPMENT PLAN PHASE 1 SOLID TUMOR IND CLEARED BY US FDA 2022 2023 2023 2024 2024 2025 2025 2026 Q3/4 Q1/2 Q3/4 Q1/2 Q3/4 Q1/2 Q3/4 Q1/2 Dose Escalation Single Ascending Doses Expansion Multiple Doses All Comers Then Focus Ph1b Combination Checkpoint / Targeted Abs / Chemo? Key M
Slide 13: Decoy Therapy Significantly Reduces LPS-Endotoxin Activity and Pyrogenicity
DECOY THERAPY SIGNIFICANTLY REDUCES LPS-ENDOTOXIN ACTIVITY AND IN VIVO PYROGENICITY COMPARED TO LIVE BACTERIA Decoy therapeutics are also 100- to 2,500-fold less toxic in mice (LD50) than several live, attenuated bacterial products Live LPS Endotoxin Activity Pyrogenicity Threshold Treatment Bacteri
Slide 14: LPS Reduction Does Not Impair Anti-Tumor Cytokine/Chemokine Induction
LPS REDUCTION DOES NOT IMPAIR ANTI-TUMOR CYTOKINE/CHEMOKINE INDUCTION Despite being less toxic, Decoy therapeutics induce Decoy therapeutics are more broadly active similar amounts of anti-tumor cytokines and than mono-specific TLR agonists chemokines, uncoupling toxicity from anti-tumor activity Se
Slide 15: Single Agent Activity - Metastatic Mouse Pancreatic Carcinoma
SINGLE AGENT ACTIVITY - METASTATIC MOUSE PANCREATIC CARCINOMA No Decoy Decoy Gem 100 Treatment 5x10^7 2x10^8 No Treatment Median 35 Days 41 Days 75 Days 27 Days Survival P<0.01 P<0.01 P<0.01 80 Gemcitabine 50 mg/kg Percent Survival Log-Rank Test Percent Survival Decoy20 vs. No Treatment Decoy20 Deco
Slide 16: Decoy + NSAID Safely Eradicates Subcutaneous Mouse HCC
DECOY + NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) SAFELY ERADICATES SUBCUTANEOUS MOUSE HEPATOCELLULAR CARCINOMAS (HCC) Treat 6 mice per group with Decoy 2x per week i.v. for 7 weeks / Start treatment at 103 mm3 4,000 4,000 Vehicle Decoy Tumor Volume (mm3) Tumor Volume (mm3) 3,000 Control 3,000 2x
Slide 17: Combination with Anti-PD-1 Produces Up to 100% Complete Responses with HCC
COMBINATION WITH ANTI-PD-1 CHECKPOINT THERAPY PRODUCES UP TO 100% COMPLETE RESPONSES WITH HCC 3,500 3 ± SEM) Control Control (6 mice per Indomethacin group)also received NSAID All animals 3 SEM) 3,000 Decoy 2x10^8 Indomethacin i.v. 1xDecoy10 + 2x10^8 per week x6 x6 1x/week Anti-PD-1 1/6 CR (mm Anti-
Slide 18: Synergistic Eradication of Murine HCC Exhibits Wide Therapeutic Index
SYNERGISTIC ERADICATION OF MURINE HCC EXHIBITS A VERY WIDE DECOY THERAPEUTIC INDEX (≥33-FOLD) All Decoy-treated groups also received the same standard regimen of mouse anti-PD-1 No Treatment (6 mice per group) 3x107 Decoy 1x108 Decoy 4,000 1,000 1,000 Tumor Volume (mm3) Tumor Volume (mm3) Tumor Volu
Slide 19: Cured Mice Re-Challenged with HCC Cells Reject Tumors (Immunological Memory)
MOUSE CURED BY DECOY + NSAID + CHECKPOINT INHIBITOR AND RE- CHALLENGED WITH FRESH HCC TUMOR CELLS REJECT THE TUMORS (IMMUNOLOGICAL MEMORY) Eleven Cured Mice were Re-Challenged with Six Naïve Mice were Challenged Fresh HCC Tumor Cells on Day 91 on the Opposite with the Same Tumor Cells as the Cured M
Slide 20: Mouse NHL Tumors Cured by Decoy + Low-Dose Chemotherapy
MOUSE NON-HODGKINS LYMPHOMA (NHL) TUMORS WERE CURED BY DECOY + LOW-DOSE CHEMOTHERAPY AND RE-CHALLENGED WITH FRESH NHL TUMOR CELLS REJECT THE TUMORS (IMMUNOLOGICAL MEMORY) 2,000 Tumor Cell Re-Challenge on Opposite Flank of 8 Tumor Cell-Matched Challenge Cured Mice of 5 Naive Mice on Day 77 on Day 77
Slide 21: Decoy Technology Also Regresses Human NHL Tumor Xenografts
DECOY TECHNOLOGY ALSO REGRESSES HUMAN NON-HODGKINS LYMPHOMA TUMOR XENOGRAFTS Treat 5 mice per group 2x per week for 3 weeks / Start treatment at 173 mm3 5,000 SEM) Rituximab 2x per week i.p. x 3 NHL standard of care 4,000 Control Control Mean Tumor Volume (mm3 LDC LDC (20 mg/kg) 3,000 Decoy(2x10^8)
Slide 22: Potential Utility as Anti-Viral Therapy: HBV, HIV and Others
POTENTIAL UTILITY AS ANTI-VIRAL THERAPY HEPATITIS B VIRUS (HBV), HIV AND OTHERS • HBV is a chronic liver infection affecting 257 million people world-wide ⎼ Only 2% treated with current therapies / Major cause of cirrhosis and HCC / 887,000 deaths per year • Cytokines have strong anti-viral activity
Slide 23: Target Indications Include 6 of the World's 12 Deadliest Cancers
TARGET INDICATIONS INCLUDE 6 OF THE WORLD’S 12 DEADLIEST CANCERS 12 Deadliest Cancers World-Wide (Decoy Targets) High Unmet Medical Need % of Yearly % of Yearly Deaths Cases 3% - 17% 1 Lung 18.4 11.6 2 Colorectal 9.0 10.0 3 Stomach 8.2 5.7 Percent five-year survival 4 Liver 8.2 4.7 for patients with
Slide 24: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM Leadership experience in new modalities and early development Jeffrey Meckler - Chief Executive Officer Jeffrey Meckler currently serves as our Chief Executive Officer, bringing more than 30 years of financial and healthcare leadership experience to the company. Most rece
Slide 25: Experienced Board of Directors
EXPERIENCED BOARD OF DIRECTORS Leadership experience in new modalities and early development Roger J. Pomerantz, M.D. - Chairman Anthony J. Maddaluna - Director W. Brad Hayes - Director Mark Gilbert - Director Hila Karah - Director Brian O’Callaghan - Director Michael Newman - Founder, CSO, Director
Slide 26: Investor & Media Relations: CORE IR
Investor & Media Relations: CORE IR Scott Birkby sbirkby@coreir.com
Indaptus Therapeutics — Investor Presentation (October 2022) on 6ix